CLAIMS

1. An oral dosage form comprising:

the compound of formula (I) or a pharmaceutically acceptable salt thereof; and

a modified-release polymer (e.g., a controlled-release polymer, hydrophilic matrix polymers, e.g., an HPMC polymer, hydrophobic matrix polymers (e.g., ethyl cellulose, ethocel), or polyacrylate polymers (e.g., Eudragit RL100, Eudragit RS100)).

2. The dosage form of claim 1, wherein the dosage form comprises from about 0.9 % by weight to about 40 % by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

3. The dosage form of claim 1 or 2, wherein the dosage form comprises from about 14% by weight to about 25% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

4. The dosage form of any one of claims 1-3, wherein the dosage form comprises from about 19% by weight to about 20% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

5. The dosage form of any one of claims 1-3, wherein the dosage form comprises from about 21% by weight to about 22% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

6. The dosage form of claim 1 or 2, wherein the dosage form comprises from about 4% by weight to about 15% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

7. The dosage form of any one of claim 1, 2, or 6, wherein the dosage form comprises from about 4% by weight to about 10% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

8. The dosage form of any one of claim 1, 2, 6, or 7, wherein the dosage form comprises from about 4% by weight to about 5% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

9. The dosage form of any one of claim 1, 2, 6, or 7, wherein the dosage form comprises from about 5% by weight to about 6% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

10. The dosage form of any one of claim 1, 2, 6, or 7, wherein the dosage form comprises from about 9% by weight to about 10% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

11. The dosage form of any one of claims 1-10, wherein the dosage form comprises from about 1 mg to about 40 mg (e.g., about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

12. The dosage form of any one of claims 1-11, wherein the dosage form comprises from about 4 mg to about 6 mg (e.g., about 5 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

13. The dosage form of any one of claims 1-11, wherein the dosage form comprises from about 15 mg to about 25 mg (e.g., about 20 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

14. The dosage form of any one of claims 1-13, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) is crystalline.

15. The dosage form of claim 14, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 16.2±0.2, 17.4±0.2, and 26.6±0.2.

16. The dosage form of claim 14 or 15, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 11.5±0.2, 16.2±0.2, 17.4±0.2, 22.6±0.2, and 26.6±0.2.

17. The dosage form of any one of claims 14-16, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 11.5±0.2, 16.2±0.2, 17.4±0.2, 18.3±0.2, 18.5±0.2, 19.2±0.2, 20.0±0.2, 22.6±0.2, 23.9±0.2, and 26.6±0.2.

18. The dosage form of any one of claims 14-17, wherein the crystalline form has a X-ray powder diffraction pattern substantially the same as depicted in FIG. 1.

19. The dosage form of any one of claims 14-18, wherein the powder X-ray diffraction pattern was obtained using Cu Kα radiation.

20. The dosage form of any one of claims 14-19, wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry at about 226.6 °C.

21. The dosage form of any one of claims 1-20, wherein the dosage form comprises from about 55 mg to 65 mg of the modified-release polymer.

22. The dosage form of any one of claims 1-21, wherein the dosage form comprises from about 10% by weight to about 70% by weight of the modified-release polymer.

23. The dosage form of any one of claims 1-22, wherein the dosage form comprises from about 50% by weight to about 60% by weight of the modified-release polymer.

24. The dosage form of any one of claims 1-23, wherein the dosage form further comprises a diluent.

25. The dosage form of claim 24, wherein the diluent comprises microcrystalline cellulose.

26. The dosage form of claim 25, wherein the dosage form comprises from about 15 mg to 40 mg (e.g., from about 15 mg to about 25 mg, from about 20 mg to about 25 mg, from about 25 mg to about 30 mg, from about 30 mg to about 40 mg) microcrystalline cellulose.

27. The dosage form of claim 25, wherein the dosage form comprises from about 15% by weight to about 35% by weight (e.g., from about 15% by weight to about 20% by weight, from about 20% by weight to about 25 % by weight, from 25% by weight to about 30% by weight, from 30% by weight to about 35% by weight) microcrystalline cellulose.

28. The dosage form of any one of claims 1-27, wherein the dosage form further comprises a glidant.

29. The dosage form of claim 28, wherein the glidant comprises colloidal silicon dioxide.

30. The dosage form of any one of claims 1-29, wherein the dosage form further comprises a lubricant.

31. The dosage form of claim 30, wherein the lubricant comprises magnesium stearate.

32. The dosage form of any one of claims 1-31, wherein the dosage form further comprises a coating.

33. The dosage form of any one of claims 1-32, wherein about 80% of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) is released within 7 hours upon administration to a subject.

34. The dosage form of claim 33, wherein about 80% of the compound of formula (I) is released in 7 hours using USP apparatus type-I, media containing 900 mL 0.1 M HCl, and a paddle speed of 100 rpm.

35. The dosage form of any one of claims 1-34, wherein the dosage form, upon administration to a subject, has a reduced C_{max} value than a reference oral dosage form (e.g., a dosage form with any intended release rate profile e.g., modified release rate profile, a dosage form that does not have a modified release rate profile, a dosage form that does not have a modified-release polymer, e.g., an HPMC polymer).

36. The dosage form of any one of claims 1-35, wherein the dosage form, upon administration to a subject, has a greater t_{max} value than a reference oral dosage form (e.g., a dosage form with any intended release rate profile e.g., modified release rate profile, a dosage form that does not have a modified release rate profile, a dosage form that does not have a modified-release polymer, e.g., an HPMC polymer).

37. The dosage form of any one of claims 1-36, wherein the dosage form is administered to a patient once daily.

38. The dosage form of any one of claims 1-36, wherein the dosage form is administered to a patient twice daily.

39. An oral dosage form comprising:

from about 15 mg to 25 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 55 mg to 65 mg of an HPMC polymer.

40. An oral dosage form comprising:

from about 14% by weight to about 25% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 53% by weight to about 64% by weight of an HPMC polymer.

41. An oral dosage form comprising:

from about 3 mg to 8 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 55 mg to 65 mg of an HPMC polymer.

42. An oral dosage form comprising:

from about 3% by weight to about 8% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 53% to about 64% by weight of an HPMC polymer.

43. The dosage form of any one of claims 1-42, wherein the dosage form is a tablet.

44. The dosage form of any one of claims 1-42, wherein the dosage form is a capsule.

45. The dosage form of any one of claims 1-42, wherein the dosage form is a suspension.

46. An oral (e.g., particulate) composition comprising:

the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

a modified-release polymer (e.g., a controlled-release polymer, hydrophilic matrix polymers, e.g., an HPMC polymer , hydrophobic matrix polymers (e.g., ethyl cellulose, ethocel), or polyacrylate polymers (e.g., Eudragit RL100, Eudragit RS100)).

47. The composition of claim 46, wherein the composition comprises from about 0.9 % by weight to about 40 % by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

48. The composition of claim 46 or 47, wherein the composition comprises from about 14% by weight to about 25% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

49. The composition of any one of claims 46-48, wherein the composition comprises about 19% by weight to about 20% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

50. The composition of any one of claims 46-48, wherein the composition comprises about from 21% by weight to about 22% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

51. The composition of claim 46 or 47, wherein the composition comprises from about 4% by weight to about 15% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

52. The composition of any one of claim 46, 47, or 51, wherein the composition comprises from about 4% by weight to about 10% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

53. The composition of any one of claim 46, 47, 51, or 52, wherein the composition comprises about 4% by weight to about 5% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

54. The composition of any one of claim 46, 47, 51, or 52, wherein the composition comprises about 5% by weight to about 6% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

55. The composition of any one of claim 46, 47, 51, or 52, wherein the composition comprises about 9% by weight to about 10% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

56. The composition of any one of claims 46-55, wherein the composition comprises from about 1 mg to about 40 mg (e.g., about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

57. The composition of any one of claims 46-55, wherein the composition comprises from about 4 mg to about 6 mg (e.g., about 5 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

58. The composition of any one of claims 46-55, wherein the composition comprises from about 15 mg to about 25 mg (e.g., about 20 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)).

59. The composition of any one of claims 46-55, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) is a crystalline form.

60. The composition of claim 59, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 16.2±0.2, 17.4±0.2, and 26.6±0.2.

61. The composition of claim 59 or 60, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 11.5±0.2, 16.2±0.2, 17.4±0.2, 22.6±0.2, and 26.6±0.2.

62. The composition of any one of claims 59-61, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 11.5±0.2, 16.2±0.2, 17.4±0.2, 18.3±0.2, 18.5±0.2, 19.2±0.2, 20.0±0.2, 22.6±0.2, 23.9±0.2, and 26.6±0.2.

63. The composition of any one of claims 59-62, wherein the crystalline form has an X-ray powder diffraction pattern substantially the same as depicted in FIG. 1.

64. The composition of any one of claims 59-63, wherein the powder X-ray diffraction pattern was obtained using Cu Kα radiation.

65. The composition of any one of claims 59-64, wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry at about an onset at about 226.6 °C.

66. The composition of any one of claims 59-65, wherein the crystalline form has a differential scanning calorimetry curve substantially the same as shown in FIG. 2.

67. The composition of any one of claims 46-66, wherein the composition comprises from about 55 mg to 65 mg of the modified-release polymer.

68. The composition of any one of claims 42-62, wherein the composition comprises from about 10% by weight to about 70% by weight of the modified-release polymer.

69. The composition of any one of claims 42-63, wherein the composition comprises from about 50% by weight to about 60% by weight of the modified-release polymer.

70. The composition of any one of claims 42-64, wherein the dosage form comprises a diluent.

71. The composition of claim 65, wherein the diluent comprises microcrystalline cellulose.

72. The composition of claim 66, wherein the composition comprises from about 15 mg to 40 mg (e.g., from about 15 mg to about 25 mg, from about 20 mg to about 25 mg, from about 25 mg to about 30 mg, from about 30 mg to about 40 mg), microcrystalline cellulose.

73. The composition of claim 66, wherein the composition comprises from about 15% to about 35% by weight (e.g., from about 15% to about 20%, from about 20% to about 25 %, from 25% to about 30%, from 30% to about 35% by weight)microcrystalline cellulose.

74. The composition of any one of claims 42-68, wherein the composition further comprises a glidant.

75. The composition of claim 69, wherein the glidant comprises colloidal silicon dioxide.

76. The composition of any one of claims 42-70, wherein the composition further comprises a lubricant.

77. The composition of claim 71, wherein the lubricant comprises magnesium stearate.

78. The composition of any one of claims 42-72, wherein the composition further comprises a coating.

79. The composition of any one of claims 42-73, wherein the compound is stable at about 25 °C at 60 % relative humidity for at least 24 months.

80. The composition of any one of claims 42-74, wherein the compound is stable at about 25 °C at 60 % relative humidity for at least 36 months.

81. The composition of any one of claims 42-75, wherein the compound is stable at about 25 °C at 60 % relative humidity for at least 48 months.

82. The composition of any one of claims 42-76, wherein the compound is stable at about 25 °C at 60 % relative humidity for at least 60 months.

83. The composition of any one of claims 42-77, wherein the compound is stable at about 40 °C at 75 % relative humidity for at least 6 months.

84. An oral (e.g., particulate) composition comprising:

from about 15 mg to 25 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 55 mg to 65 mg HPMC.

85. An oral (e.g., particulate) composition comprising:

from about 14% by weight to about 25% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 53% to about 64% by weight of an HPMC polymer.

86. An oral (e.g., particulate) composition comprising:

from about 3 mg to 8 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 55 mg to 65 mg HPMC.

87. An oral (e.g., particulate, swellable core) composition comprising:

from about 3% by weight to about 8% by weight of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)); and

from about 53% to about 64% by weight of an HPMC polymer.

88. A crystalline form of the compound of formula (II), wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 16.2±0.2, 17.4±0.2, and 26.6±0.2.

89. The crystalline form of claim 88, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 11.5±0.2, 16.2±0.2, 17.4±0.2, 22.6±0.2, and 26.6±0.2.

90. The crystalline form of claim 88 or 89, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 11.5±0.2, 16.2±0.2, 17.4±0.2, 18.3±0.2, 18.5±0.2, 19.2±0.2, 20.0±0.2, 22.6±0.2, 23.9±0.2, and 26.6±0.2.

91. The crystalline form of any one of claims 88-90, wherein the crystalline form has a X-ray powder diffraction pattern substantially the same as depicted in FIG. 1.

92. The crystalline form of any one of claims 88-91, wherein the powder X-ray diffraction pattern was obtained using Cu Kα radiation.

93. The crystalline form of any one of claims 88-92, wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry at about 226.6 °C.

94. A crystalline form of the compound of formula (II), wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 21.9±0.2, 18.5±0.2, and 17.8±0.2.

95. The crystalline form of claim 94, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 21.9±0.2, 18.5±0.2, 17.8±0.2, 10.2±0.2, and 20.5±0.2.

96. The crystalline form of claim 94 or 95, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 21.9±0.2, 18.5±0.2, 17.8±0.2, 10.2±0.2, 20.5±0.2, 25.2±0.2, 16.9±0.2, 24.2±0.2, 28.6±0.2, and 21.2±0.2.

97. The crystalline form of any one of claims 94-96, wherein the crystalline form has a X-ray powder diffraction pattern substantially the same as depicted in FIG. 7.

98. The crystalline form of any one of claims 94-97, wherein the powder X-ray diffraction pattern was obtained using Cu Kα radiation.

99. The crystalline form of any one of claims 94-98, wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry at about 97.9, 131.6, 223.7, 83.8, 128.9, 168.9, or 224.4 °C.

100. A method of treating a neurological disorder in a subject in need thereof, wherein the method comprises administering to the subject the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99.

101. The method of claim 100, wherein the neurological disorder is epilepsy.

102. The method of claim 101, wherein the epilepsy is juvenile epilepsy.

103. The method of claim 101, wherein the epilepsy is genetic epilepsy (e.g., CACNA1G related genetic generalized epilepsy).

104. The method of claim 100, wherein the neurological disorder is absence seizure.

105. The method of claim 100, wherein the neurological disorder is absence epilepsy (e.g., CACNA1H related absence epilepsy).

106. The method of claim 100, wherein the neurological disorder is epilepsy related to CACNA1G, H or I.

107. The method of claim 101, wherein the epilepsy is childhood absence epilepsy (CAE).

108. The method of claim 101, wherein the epilepsy is juvenile absence epilepsy (JAE).

109. The method of claim 101, wherein the epilepsy is Lenox-Gastaut Syndrome.

110. The method of claim 100, wherein the neurological disorder is pain (e.g., acute pain, chronic pain, neuropathic pain, inflammatory pain, nociceptive pain, central pain; e.g., thalamic pain; or migraine)

111. The method of claim 100, wherein the neurological disorder is tremor (e.g., essential tremor, Parkinson's tremor, or cerebellar tremor, CACNA1G related tremor).

112. The method of claim 100, wherein the neurological disorder is ataxia (e.g., spinocerebellar ataxia, or spinocerebellar ataxia with CACNA1G mutations).

113. The method of claim 100, wherein the neurological disorder is tinnitus.

114. The method of claim 100, wherein the neurological disorder is a disorder of wakefulness.

115. A method of treating a psychiatric disorder in a subject in need thereof, wherein the method comprises administering to the subject the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99.

116. The method of claim 115, wherein the psychiatric disorder is a mood disorder.

117. The method of claim 116, wherein the mood disorder is major depressive disorder.

118. The method of any one of claims 115-117, wherein the dosage form is administered to the subject once a day.

119. The method of any one of claims 115-118, wherein the dosage form is administered to the subject twice a day.

120. The method of any one of claims 115-119, wherein the dosage form is administered to the subject every other day.

121. The method of any one of claims 100-120, wherein about 15 mg to 25 mg (e.g., about 20 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) is administered to the subject daily.

122. The method of any one of claims 100-120, wherein about 30 mg to 50 mg (e.g., about 40 mg) of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) is administered to the subject daily.

123. The method of any one of claims 100-122, wherein the dosage form, upon administration to the subject, has a reduced C_{max} value than a reference oral dosage form (e.g., a dosage form with any intended release rate profile e.g., modified release rate profile, a dosage form that does not have a modified release rate profile, a dosage form that does not have a modified-release polymer, e.g., an HPMC polymer).

124. The method of any one of claims 100-123, wherein the dosage form, upon administration to the subject, has a greater t_{max} value than a reference oral dosage form (e.g., a dosage form with any intended release rate profile e.g., modified release rate profile, a dosage form that does not have a modified release rate profile, a dosage form that does not have a modified-release polymer, e.g., an HPMC polymer).

125. A method of treating a generalized epileptic syndrome with absence seizures in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the number of seizures.

126. A method of treating a generalized epileptic syndrome with absence seizures in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the seizure density as measured by Electroencephalogram (EEG).

127. A method of treating a generalized epileptic syndrome with absence seizures in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the mean seizure duration as measured by EEG.

128. A method of treating a generalized epileptic syndrome with absence seizures in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the cumulative seizure duration as measured by EEG.

129. A method of treating a generalized epileptic syndrome with absence seizures in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the total time with 2.5-4Hz spike wave discharges after hyperventilation and photic stimulation challenges as measured by EEG.

130. A method of treating a generalized epileptic syndrome with absence seizures in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of global severity as measured by Clinical Global Impression-Severity (CGI-S) or Clinical Global Impression-Improvement (CGI-I) scores.

131. A method of treating an essential tremor in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the essential tremor as assessed by The Essential Tremor Rating Assessment Scale (TETRAS) score.

132. The method of claim 131, wherein the reduction of the essential tremor is assessed by The Essential Tremor Rating Assessment Scale (TETRAS) upper limb score.

133. The method of claim 131, wherein the reduction of the essential tremor is assessed by TETRAS-ADL (activities of daily living).

134. The method of claim 131 or 132, wherein the reduction of the essential tremor is assessed by TETRAS performance subscale score or TETRAS performance individual items.

135. A method of treating an essential tremor in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of the essential tremor as assessed by accelerometer-based upper limb score.

136. A method of treating an essential tremor in a patient in need thereof, comprising administering to the patient a sufficient amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof (e.g., the compound of formula (II)) (e.g., the oral dosage form of any one of claims 1-45, the composition of any one of claims 46-87, or the crystalline form of any one of claims 88-99) that results in reduction of sigma frequency band.

137. The method of any one of claims 131-136, wherein the essential tremor is upper limb tremor.